Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EuroapiXPAR:EAPI -0.78%59 Cash-to-Debt is 1.83 as of Dec. 2025, which is 59% above its 10-year median of 1.15. GuruFocus rates XPAR:EAPI with a GF Score™ of 59/100 and a GF Value™ of €2.88 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 985 Drug Manufacturers companies, Euroapi ranks better than 58.58% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Euroapi's cash to debt ratio for the quarter that ended in Dec. 2025 was 1.83.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Euroapicould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Euroapi's Cash-to-Debt or its related term are showing as below:
XPAR:EAPI'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19 Med: 1.15 Max: 2.1
Current: 1.83
During the past 7 years, Euroapi's highest Cash to Debt Ratio was 2.10. The lowest was 0.19. And the median was 1.15.
XPAR:EAPI's Cash-to-Debt is ranked better than 58.58% of 985
companies
in the Drug Manufacturers industry
Industry Median: 1
vs XPAR:EAPI: 1.83
Euroapi (XPAR:EAPI) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Euroapi Cash-to-Debt Related Terms
Euroapi Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Euroapi's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XPAR:EAPI vs ZTS, UTHR, VTRS: Cash-to-Debt Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euroapi's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euroapi Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euroapi's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Euroapi's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Euroapi (XPAR:EAPI) has a Cash-to-Debt of 1.83 as of Dec. 2025. This is 59% above median its historical median of 1.15. Over the past decade, Euroapi's Cash-to-Debt has ranged from 0.19 to 2.10. According to the industry distribution chart, Euroapi ranks #408 out of 985 companies in the Drug Manufacturers industry, placing it in the top 41.4%.
Is Euroapi's Cash-to-Debt too high?
Euroapi's current Cash-to-Debt of 1.83 is 59% above median its 10-year median of 1.15. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 2.10. The Drug Manufacturers industry median Cash-to-Debt is 1.00. Euroapi's value of 1.83 is 83% above this industry median. Based on the distribution chart, Euroapi ranks #408 out of 985 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Euroapi has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euroapi ranks #408 out of 985 companies for Cash-to-Debt. This puts Euroapi in the upper half of its industry. The industry median Cash-to-Debt is 1.00. Euroapi's value of 1.83 is 83% above this benchmark. Historically, Euroapi's own Cash-to-Debt has ranged from 0.19 to 2.10 over the past decade. While the company's 10-year median is 1.15 vs. the industry median of 1.00, Euroapi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 1.00, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euroapi's current Cash-to-Debt of 1.83 is 83% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 1.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euroapi's current Cash-to-Debt is 1.83, which is 59% above median its own 10-year median of 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (XPAR:EAPI) is currently considered Possible Value Trap. The stock's GF Value™ is €2.88, compared to a current price of €1.26 — trading 56.1% below its estimated fair value. The current Cash-to-Debt is 1.83, which is 59% above median its 10-year median of 1.15 and 83% above the Drug Manufacturers industry median of 1.00. Euroapi's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Euroapi (XPAR:EAPI), the current Cash-to-Debt is 1.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euroapi (XPAR:EAPI) Overvalued in 2026?
Based on GuruFocus' analysis, Euroapi stock appears to be undervalued.
The current stock price of €1.26 is trading 56.1% below its estimated GF Value™ of €2.88.
GuruFocus considers Euroapi to be Possible Value Trap.
Key valuation signals for XPAR:EAPI:
Cash-to-Debt: 1.83 (59% above median its 10-year median of 1.15)
GF Value™: €2.88 vs. price of €1.26 (56.1% below fair value)
Industry Position: 83% above the Drug Manufacturers median (#408 of 985)
No single metric tells the full story. See the XPAR:EAPI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
59GF Score
Get the complete analysis for XPAR:EAPI
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:EAPI has been successfully added to your 
